Navigation Links
Elbit Imaging Ltd. Announces First Quarter Results for 2008
Date:5/29/2008

,173 13,108 68,139 5,115

Decrease in shareholding of

investees - - 5,310 -

195,159 558,365 3,498,561 54,929

Costs and expenses

Commercial centers(1) 40,806 419,831 1,714,253 11,485

Hotels operations and management 81,626 81,582 330,063 22,974

Cost and expenses of medical

systems operation 14,983 17,763 69,953 4,217

Cost of fashion merchandise 22,697 17,413 80,308 6,388

Research and development expenses,

net 16,166 16,142 69,559 4,550

General and administrative expenses 8,551 16,416 116,992 2,407

Share in losses of associates, net 2,318 4,496 12,667 652

Financial expenses, net 12,113 22,654 140,925 3,409

Other expenses, net (1,854) (3,475) 38,233 (522)

197,406 592,821 2,572,953 55,560

Profit (loss) before income taxes (2,247) (34,456) 925,608 (631)

Income taxes (tax benefits) 3,055 (279) 16,288 860

Profit (loss) from continuing

operations (5,302) (34,177) 909,320 (1,491)

Profit from discontinued operation,

net 1,754 170 10,288 494

Profit (loss) for the period (3,548) (34,007) 919,608 (997)

Attributable to:

Equity holders of the Company (27,348) (40,693) 539,749 (7,695)

Minority interest 23,800 6,686 379,859 6,698

(3,548) (34,007) 919,608 (997)

(1) Sale of trading property and investment property operations

Elbit Imaging Ltd
'/>"/>

SOURCE Elbit Imaging Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Elbit Medical Imaging Ltd. Announces Publication of a Prospectus in Israel
2. Elbit Medical Imaging Ltd. Announces Adjournment of its Annual General Meeting
3. Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing
4. Elbit Imaging Ltd. Selected for Listing on Nasdaq Global Select Market
5. Elbit Imaging Ltd. Announces Termination of Service of Trustee for Holders of Series A, B and C Notes
6. Brain imaging reveals breakdown of normal emotional processing
7. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
8. Fry Construction Selected for High-Profile Medical Imaging Project
9. Ultrasonix Adds Global Medical Imaging Into Its North American Sales Force
10. Imaging Software Helps Track, Treat Injured Brains
11. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...ndenses the blood and increases the risk of heart ...versity of Texas, it has been found that too many ... - in Britain. He believes that cold temperatures ...s thicker than normal. This raises the risk of clo...
...ecognised an amino-acid taste receptor.Dr Charles ... and the University of California, San Diego, repo... can identify five different tastes — bitter, salt...ur associated with monosodium glutamate (MSG).Rece...
...ke and have a history of alcohol problems have poo...most 400 patients// to find if there was a link be...ified them into four groups:current tobacco use on...th, or neither. The patients with both current to...
... that an air pollutant emitted by power plants and...ng can increase your chances of dying from lung ca...icles of air pollution. The study authors contend ...you to "fine particulate matter" that makes its wa...
Other Medicine News:Health News:Comprehension of taste receptor, 2
(Date:9/3/2008)...- Simcere,Pharmaceutical Gr...lier of,branded generic pharmaceuticals and manufa... Endu (also known as Endostar) in China,announced...dy., At the request of the SFDA, Simcere initiate...e safety and therapeutic efficacy of Endu, a modif...
(Date:9/3/2008)...EVA, Sept. 3 /- Artelis SA and,Selexi...monoclonal antibody,production with the achievemen...er. This record level was accomplished by applying...rformance stable Selexis CHO,production cell line ...t,Selexis SA using their proprietary Selexis Genet...
(Date:9/3/2008)...s, Updates Zingo Launch Progress and Adlea ... Conference Call Today at 11:30 am ET, SOUTH...all/ -- Anesiva,Inc. (Nasdaq: ANSV ) announced t...to focus on commercial and late-stage product deve...y pharmaceutical pain management,company. The comp...
(Date:9/2/2008)...wire-FirstCall/ -- Forest Laboratories, Inc.,(NYSE...ounced results from,two global Phase III studies o...anticholinergic for the treatment of patients with...both the ACCLAIM/COPD I&II,(AClidinium CLinical Tr...evere COPD Patients) studies, once-daily aclidiniu...
Breaking Medicine Technology:Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Climate change has major impact on oceans 2245 1Climate change has major impact on oceans 2245 2Climate change has major impact on oceans 2245 3Climate change has major impact on oceans 2245 4Large changes needed to address global obesity epidemic 12109 1Large changes needed to address global obesity epidemic 12109 2Symposium on drug resistant diseases set for annual AAAS conference 12105 1MIT professor to discuss future of biofuels 2238 1MIT professor to discuss future of biofuels 2238 2
..., 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX),...inded, placebo-controlled phase 2 clinical trials ...d rheumatoid,arthritis (RA) will be featured at th...l Congress of Rheumatology meeting, June,13-16, 20...Satellite Symposium, Room 111, Thursday, June 14, ...
...Waltham, Mass., June 7, 2007 – Dynogen Pharm...randomized, double-blind,placebo-controlled Phase...sease (GERD). The study was designed to demonstra...nocturnal GERD,(NGERD). The 0.5 mg dose of DDP73...n the primary endpoint of reduction in,the number ...
Other Medicine Technology:Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 2Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 3Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study 2Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study 3
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
Medicine Products: